A strong signal for Germany as a pharmaceutical hub!

📍Berlin – A strong signal for Germany as a pharmaceutical hub!!

At the initiative of the German Pharmaceutical Association we were invited to the Federal Ministry for Economic Affairs and Energy (BMWE) to discuss the future of industrial biotechnology with representatives from the Federal Ministry of Health (BMG).

Our shared focus: ensuring European sovereignty in the highly dynamic field of cell and gene therapies (CGT / ATMPs) in the long term. There is a consensus: to prevent groundbreaking innovations and valuable IP from moving abroad, Europe urgently needs strong, scalable domestic production capacities.

We at Nordmark are ready to take on this responsibility as an established pharmaceutical company. Our goal is to use innovative and integrated production concepts to make the complex supply chains for cell and gene therapies more robust, reduce dependencies on third countries, and bridge the translational gap between research and patient care.

Many thanks to the representatives from the BMWE and BMG for the highly constructive exchange, as well as to Pharma Deutschland for initiating this important dialogue and for our shared commitment to our business location! 🤝